Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Frenlosirsen - Ionis Pharmaceuticals

Next Previous
Drug Profile

Frenlosirsen - Ionis Pharmaceuticals

Alternative Names: Frenlosirsen sodium; ION-251; ION-935918; IONIS-IRF4-2.5Rx; IRF4rx

Latest Information Update: 06 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ionis Pharmaceuticals
  • Class Antineoplastics; Antisense oligonucleotides
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Multiple myeloma

Most Recent Events

  • 25 Apr 2025 Efficacy and adverse events data from a phase I trial in Multiple myeloma presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
  • 30 Sep 2024 Ionis Pharmaceuticals completes a phase-I clinical trials in Multiple myeloma (In adults, Second-line therapy or greater) in USA (IV) (NCT04398485)
  • 28 Jan 2024 No recent reports of development identified for phase-I development in Multiple-myeloma(Second-line therapy or greater, In adults) in USA (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top